New combo targets lung cancer that morphs after treatment
NCT ID NCT07001995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of the targeted drug limertinib plus chemotherapy (etoposide and carboplatin) in 30 people with a specific type of lung cancer. These patients have a mutation in the EGFR gene and their cancer has changed from non-small cell to small cell lung cancer after standard treatment stopped working. The goal is to see if this new combo can slow down the cancer or shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- limertinib combined with etoposide and carboplatin
- What this could lead to
- If successful, this could offer a new treatment option for patients whose lung cancer has changed form and stopped responding to standard targeted therapy.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects and may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yongchang Zhang
Changsha, Hunan, 410013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?